Healthcare / Pharmaceutical RetailersNasdaqGS
$2.17
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-194000.00 · quality 38.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$46M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.4%
↓Gross Margin
30.5%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-0.2%
FCF / Net income
0.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $227.0M · net income $-6.3M · FCF $-395000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $227.0M | $227.0M | $274.1M | $247.6M | $272.3M | — | — | — | $273.8M | $249.2M | $234.7M | — | — | — | — | — | — |
| Net Income | $-6.3M | $-6.3M | $-7.5M | $5.1M | $18.7M | $23.9M | $25.9M | $37.7M | $37.3M | $23.8M | $20.6M | $17.5M | $18.0M | $17.2M | $16.7M | $20.9M | $26.0M |
| EBITDA | $5.5M | $5.5M | $-1.1M | $9.6M | $27.0M | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.30 | -0.30 | -0.37 | 0.01 | 1.04 | 1.19 | 1.29 | 1.84 | 1.82 | 1.17 | 1.02 | 0.87 | 0.90 | 0.86 | 0.80 | 0.92 | 1.14 |
| Gross Margin | 30.5% | 30.5% | 30.9% | 30.9% | 28.3% | — | — | — | 35.7% | 31.8% | 32.5% | — | — | — | — | — | — |
| Operating Margin | -0.7% | -0.7% | -3.0% | 2.4% | 8.9% | — | — | — | 19.0% | 15.0% | 13.8% | — | — | — | — | — | — |
| Net Margin | -2.8% | -2.8% | -2.7% | 2.1% | 6.9% | — | — | — | 13.6% | 9.6% | 8.8% | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | — | — | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | — | — | 0.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-395000.00 | $-395000.00 | $-194000.00 | $22.5M | $16.7M | $37.6M | $36.5M | $44.5M | $36.7M | $36.6M | $923000.00 | — | — | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | -7.4% | -7.4% | -7.7% | 4.7% | 15.2% | 19.1% | 21.5% | 28.0% | 32.2% | 25.5% | 24.7% | 23.1% | 25.6% | 26.8% | 20.5% | 21.5% | 26.8% |
| Valuation | |||||||||||||||||
| P/E | — | — | — | 1539.00 | 24.34 | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | — | 21.77 | 14.95 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | — | — | 0.46 | 2.85 | 4.17 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | -17.2% | -17.2% | 10.7% | -9.1% | — | — | — | — | 9.9% | 6.2% | — | — | — | — | — | — | — |
| EPS Growth | 18.9% | 18.9% | -3800.0% | -99.0% | — | -7.8% | -29.9% | 1.1% | 55.6% | 14.7% | 17.2% | -3.3% | 4.7% | 7.5% | -13.0% | -19.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.37 → -0.30
Residual
-41.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.